It’s time once again for Fierce Pharma Marketing’s annual #FierceMadness tournament. This time around, we're watching 64 ...
With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket ...
Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...
While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a | ...
In its 100th year in operation, family-run Recordati is considering a buyout offer from CVC Capital Partners. | CVC Capital ...
There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from Bayer’s consumer health division. | There’s no need to dive fast and furious ...
Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday ...
Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in ...
After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can ...
Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant ...
Novartis is facing a class-action lawsuit alleging it shared, without patients’ consent, sensitive health information it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results